The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) and Scientific Education Support (SES) are delighted to reveal a new array of Waldenstrom’s macroglobulinemia (WM) content is now available on the Lymphoma Hub as part of the WM Awareness-Building Initiative.
The objective of this initiative is to provide healthcare professionals around the world with the support to make informed treatment decisions and ensure patients have access to the latest treatments and support.
The new content includes a visual abstract on a phase I/II trial of pirtobrutinib in patients with R/R WM (BRUIN trial) and an article on the treatment landscape for relapsed/refractory WM. The IWMF’s “Talking with your WM patients” resource is also now available on the Lymphoma Hub, along with a visual summary of the guide.
The IWMF and Lymphoma Hub are working in partnership to raise awareness of WM amongst healthcare professionals, patients, caregivers and the patient advocacy community.
This initiative and associated content has been funded by Cellectar Biosciences. All content has been created independently by SES in collaboration with an expert steering committee and funders have had no direct influence on the content of the hub.
![](https://smebulletin.com/wp-content/uploads/2018/06/ivinr.jpeg)
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.